Jayaraj Vivek Jason, Rampal Sanjay, Ng Chiu-Wan, Chong Diane Woei Quan
Centre for Epidemiology and Evidence-based Practice, Department of Social and Preventive, Medicine, Faculty of Medicine, University of Malaya, 50603 Kuala Lumpur, Malaysia.
Ministry of Health Malaysia, Putrajaya, Malaysia.
Lancet Reg Health West Pac. 2021 Dec;17:100295. doi: 10.1016/j.lanwpc.2021.100295. Epub 2021 Oct 21.
COVID-19 has rapidly spread across the globe. Critical to the control of COVID-19 is the characterisation of its epidemiology. Despite this, there has been a paucity of evidence from many parts of the world, including Malaysia. We aim to describe the epidemiology of COVID-19 in Malaysia to inform prevention and control policies better.
Malaysian COVID-19 data was extracted from 16 March 2020 up to 31 May 2021. We estimated the following epidemiological indicators: 7-day incidence rates, 7-day mortality rates, case fatality rates, test positive ratios, testing rates and the time-varying reproduction number (Rt).
Between 16 March 2020 and 31 May 2021, Malaysia has reported 571,901 cases and 2,796 deaths. Malaysia's average 7-day incidence rate was 26•6 reported infections per 100,000 population (95% CI: 17•8, 38•1). The average test positive ratio and testing rate were 4•3% (95% CI: 1•6, 10•2) and 0•8 tests per 1,000 population (95% CI: <0•1, 3•7), respectively. The case fatality rates (CFR) was 0•6% (95% CI: <0•1, 3•7). Among the 2,796 cases who died, 87•3% were ≥ 50 years.
The public health response was successful in the suppression of COVID-19 transmission or the first half of 2020. However, a state election and outbreaks in institutionalised populations have been the catalyst for more significant community propagation. This rising community transmission has continued in 2021, leading to increased incidence and strained healthcare systems. Calibrating NPI based on epidemiological indicators remain critical for us to live with the virus. (243 words).
This study is part of the COVID-19 Epidemiological Analysis and Strategies (CEASe) Project with funding from the Ministry of Science, Technology and Innovation (UM.0000245/HGA.GV).
新冠病毒病(COVID-19)已在全球迅速传播。了解其流行病学特征对于控制COVID-19至关重要。尽管如此,包括马来西亚在内的世界许多地区仍缺乏相关证据。我们旨在描述马来西亚COVID-19的流行病学情况,以便更好地为预防和控制政策提供依据。
提取2020年3月16日至2021年5月31日期间马来西亚的COVID-19数据。我们估算了以下流行病学指标:7天发病率、7天死亡率、病死率、检测阳性率、检测率以及随时间变化的繁殖数(Rt)。
在2020年3月16日至2021年5月31日期间,马来西亚报告了571,901例病例和2,796例死亡。马来西亚的平均7天发病率为每10万人中有26.6例报告感染(95%置信区间:17.8, 38.1)。平均检测阳性率和检测率分别为4.3%(95%置信区间:1.6, 10.2)和每1000人0.8次检测(95%置信区间:<0.1, 3.7)。病死率为0.6%(95%置信区间:<0.1, 3.7)。在2796例死亡病例中,87.3%的患者年龄≥50岁。
2020年上半年,公共卫生应对措施成功抑制了COVID-19的传播。然而,一次州选举以及机构化人群中的疫情爆发成为了更广泛社区传播的催化剂。这种社区传播的上升在2021年仍在持续,导致发病率增加,医疗系统不堪重负。根据流行病学指标校准非药物干预措施对于我们与病毒共存仍然至关重要。(243字)
本研究是COVID-19流行病学分析与策略(CEASe)项目的一部分,由科学、技术和创新部(UM.0000245/HGA.GV)资助。